Fig. 7

Immune cell alterations associated with cetuximab treatment in HNSCC patients. a 22 matched pairs (15 pairs were from non-responders and 7 pairs were from responders) of pre-treatment biopsies and on-treatment (cetuximab) specimens were obtained as FFPE sections on glass slides. Representative images of Vectra 3.0 staining of patient tumors before and following 3–4 weeks of cetuximab treatment. b InForm analysis of immune cell content in primary HNSCC pre- and post-cetuximab treatment. Each data point is the mean of 5–15 distinct regions of interest within each tumor section and the resulting data were submitted to a paired T test